Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Association of Hypertriglyceridemia With Renal Function Decline and the Development of End-Stage Kidney Disease in a Real-World Clinical Setting
  2. Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension
  3. Aspirin vs Clopidogrel for Long-Term Maintenance After Coronary Stenting in Patients With Diabetes
  4. Subclinical Coronary Atherosclerosis and the Risk for Myocardial Infarction
  5. Separate and Combined Effects of Semaglutide and Empagliflozin on Kidney Oxygenation and Perfusion in People With Type 2 Diabetes
  6. Changes in Cardiorespiratory Fitness and Survival in Patients With or Without CVD
  7. Inflammation Contributes to Cardiovascular Risk in Patients Receiving Statin Therapy
  8. Differential Effect of Anticoagulation According to Cognitive Function and Frailty in Older Patients With Atrial Fibrillation
  9. Risk of Incident Diabetes After COVID-19 Infection
  10. Effect of a Longer Time in Blood Pressure Target Range on Cardiovascular Outcomes Among Patients With Type 2 Diabetes

Most Read This Week

Recently Updated